-
Posted by
Two Blokes Jul 25 -
Filed in
Stock
-
1 view
Mineralys Therapeutics, Inc. (MLYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
